Even though PAM-targeted agents, particularly PI3K drug inhibitors, have demonstrated significant therapeutic activity in human cancer, acquired and intrinsic resistance has hindered their clinical efficacy [334–336]. The gene discussed is PIK3CB; the disease is cancer.